logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics CEO on £40mln fundraise

Ali Mortazavi, the chief executive of Silence Therapeutics (LON:SLN), discusses the £40mln conditional fundraising with Proactive Investors.

He reveals that institutional investors took part in the placing for £27.3mln, which is subject to shareholder approval. The amount raised could rise to £40mln or so if the demand is there, with an option granted to the joint bookrunners to find subscribers for an additional 5.3mln shares.

Quick facts: Silence Therapeutics PLC

Price: 386 GBX

AIM:SLN
Market: AIM
Market Cap: £302.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics boss very pleased with latest drug results

Silence Therapeutics PLC (LON:SLN OTCMKTS:SLNCF) chief executive Ali Mortazavi told investors this week its flagship drug has the potential to become a new oncology treatment. This followed the publication of detailed findings from its long-awaited phase IIa clinical...

on 04/08/2016

RNS

Holding(s) in Company

1 day, 5 hours ago

Additional Listing

2 weeks, 1 day ago

Additional Listing

2 weeks, 6 days ago

Holding(s) in Company

on 10/14/2019

Grant of share options

on 10/07/2019

Holdings in Company

on 10/07/2019

2 min read